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Intrahepatic cholangiocarcinoma is a usually fatal malignant
neoplasm originating from biliary epithelia or cholangiocytes, and
constitute about 5% of primary liver cancers (Wittekind et al,
1995). To date, however, the cellular and molecular mechanisms
leading to oncogenesis of cholangiocytes remain unclear.
Increasing evidence exists that carcinogenesis must be understood
in terms of accumulation of mutations in regulatory genes,
including activation of oncogenes and inactivation or loss of
tumour suppressor genes. Among the available candidates, the p53
gene has come to be known as a ‘master guardian of the genome’,
because of its role in regulating of cell growth and death (Harris,
1996). Recently, a new gene with significant homology to p53 has
been discovered and named p73 (Kaghad et al, 1997). This gene
mapped to the short arm of chromosome 1. It has also been
reported recently that p73 can – at least when overproduced – acti-
vate the transcription of p53-responsive genes and inhibit cell
growth, in a p53-like manner by inducing apoptosis (Jost et al,
1997). But unlike p53, no significant mutation of the p73 has been
found in human tumours. In lung cancer, activation of a silent
allele and overexpression of wild type p73 has been reported
recently (Mai et al, 1998; Nomoto et al, 1998).
No data describing the expression of p73 in cholangiocellular
carcinomas in correlation to the mutation status of p53 have so far
been reported. We therefore performed immunohistochemistry for
the p73 protein expression, p53 mutation analysis and also
survival analysis in patients with cholangiocellular carcinoma of
the liver.
MATERIALS AND METHODS
Patients and tissue samples
Forty-one patients with cholangiocellular carcinoma (CCC) under-
going partial hepatectomy (segmental or lobar resection) between
1994 and 1997 were included in this retrospective study.
No patient received preoperative or adjuvant chemo- or radio-
therapy. All patients underwent surgery in curative intent (R0
resections). Patients who received orthotopic liver transplantation
were excluded from this study.
Each tumour was re-evaluated in regard to typing, staging and
grading (WHO, 1994). Tumour typing and staging was performed
using WHO and UICC (1997) criteria respectively. In addition,
every tumour was examined macro- and microscopically for the
presence of vascular invasion, satellites, multiplicity, inflamma-
tory reaction, necrosis and dysplasia in the surrounding liver tissue
and cirrhosis. In all cases, slides prepared from four different
paraffin blocks of tissue, sampled from different tumour areas,
were examined. Pathohistological data are summarized in Table 1.
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Summary p73, the first homologue of the tumour suppressor protein p53, was recently discovered on chromosome 1p36 and has been
shown to induce apoptosis in a p53-like manner. The present study was performed with the aim of investigating the expression of p53, its new
homologue p73 and the occurrence of apoptosis in cholangiocellular carcinoma. Protein levels of p73 were examined in 41 patients with
curatively (R0-) resected cholangiocellular carcinomas with an antiserum, raised against a peptide in the N-terminal domain of p73. The
incidence of mutations in the p53 gene was analysed by direct sequencing and also immunohistochemically. Apoptotic cell death was
assessed using in-situ end-labelling (ISEL) technique in combination with morphological criteria. The results obtained were correlated with
patient survival. Immunostaining of p73 protein was detected in 17/41 carcinomas examined (41%). The immunoreactivity was confined to the
cell nucleus. In 15/41 patients (37%), mutations of the p53 gene were observed. Eleven out of these 15 patients stained also positive for p73.
In contrast, out of 26 patients without any detectable p53 mutation, only six exhibited p73 immunostaining. We failed to observe a correlation
between p73 expression or p53 and apoptosis within a given tumour. Survival analysis including the parameters stage and grade of disease,
p73 and p53, and also apoptosis, showed that tumour stage and grade as well as p53 and p73 were significantly related to prognosis. In Cox
regression survival analysis, however, only extent of primary tumour and lymph node status had an independent prognostic impact. Our
results with a high prevalence of p73 within tumours harbouring mutated p53 gene suggest that p73 could compensate for p53 function. We
failed to establish p73 or p53 as independent prognostic factors in cholangiocellular carcinoma of the liver.
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The rabbit polyclonal p73 antibody was raised against a 14 amino
acid peptide in the N-terminal part of p73 in which p73 is different
from p53. The amino acid sequence of the peptide is specified as
follows: NH2-FHLEGMTTSVMAQF-COOH. The p73 antiserum
is not cross-reactive with p53. Western blot analysis was
performed as described before (Tannapfel et al, 1998) using lysate
from seven cholangiocellular carcinomas to show protein bands,
specific for p73 and p73a (Figure 1, left). The lysate of the same
tumours were used for Western blot against p53 (Figure 1, right).
p53 sequencing
DNA was extracted according to standard procedures (Sambrook
et al, 1989) from tumour and corresponding non-neoplastic liver.
Inasmuch as 98% of p53 gene mutations in diverse types of
cancers have been found in exons 5–9, we focused our study on
these exons (Harris 1996). Each exon from 4 to 9 of the p53 gene
was amplified by 35 cycles of polymerase chain reaction (PCR)
using 5¢-end-labelled primers and Taq polymerase (Perkin
Elmer/Cetus, Norwalk, CT, USA). The following primers were
used to amplify p53 exons 4–9: exon 4: 5¢CCT GTG GGA AGC
GAA AA 3¢ and 5¢GCA AGA AGC CCA GAC GGA AAC 3¢;
exon 5: 5¢ TGT TCA CTT GTG CCC TGA CT 3¢ and 5¢CAG CC
TGT CGT CTC TCC AG 3¢; exon 6: 5¢ TGG TTG CCC AGG
GTC CCC AG 3¢ and 5¢ TTA ACC CTT CTT CCC AGA GA 3¢;
exon 7: 5¢ CCC CTG CTT GCC ACA G 3¢ and CTA CTC CCA
ACC ACC CTT GT 3¢; exon 8/9: 5¢ AAG GGT GGT TGG GAG
TAG A 3¢ and 5¢ AAA CGG CAT TTT GAG TGT TAG 3¢. In
difficult cases, nested PCR was used for minimizing the back-
ground during sequencing. The sequences of all primers used for
amplification are available from the authors upon request. DNA
sequencing of the PCR products were performed using the
DNA-Sequenase-Kit (Amersham, Germany) and an automatic
sequencing analyser (ABI 373; Applied Biosystems-Perkin-Elmer,
Germany).
Immunohistochemical analysis and assessment
Immunohistochemistry and in-situ end-labelling (ISEL) technique
was performed according to previously published methods from
tumour and corresponding non-tumourous tissue (Tannapfel et al,
1996, 1998). Apoptosis assessment was performed using the
following labelling mixture after proteinase K digestion (Sigma-
Aldrich BiochemicalsR, St Louis, MO, USA): 0.01 mM each of
dATP, dCTP, dGTP, and fluorescein-labelled dUTP (Boehringer
MannheimR, Germany), 5 mM magnesium chloride; 10 mM b-
mercaptoethanol; 5 mg ml–1 bovine serum albumin; and 20 units ml–1
Klenow DNA polymerase fragment (Boehringer MannheimR,
Germany).
For immunohistochemistry, the sections were with the primary
antiserum against p73 or the p53-antibody respectively (p53:
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Table 1 Patients and pathohistological data
No. of patients 1-year survival Median survival Odds ratio
rate (%) (95% CI) (95% CI) (days) (crude)
All 41 31 (17–45) 210 (156–264)
Stage
I 1/41 (5%) 100 Patient alive (after 1596 days)a
II 7/41 (15%) 100 Seven patients alive (after 257–1323 days)
IIIA 21/41 (51%) 24 (0–44) 210 (134–286)
IIIB 3/41 (7%) 0 80 (48–112)
IVA 9/41 (22%) 0 89 (0–47)
pT-category
1/2 8/41 (20%) 100 All alive
3/4 33/41 (80%) 15 (3–27) 159 (111–107)a
pN-category
0 32/41 (78%) 40 251 (215–287)
1 9/41 (22%) 0 80 (56–104) 8.4 (3.4–20.4)
Grading
G1 14/41 (34%) 48 (21–75) 369
G2 21/41 (51%) 20 (4–36) 156 (71–241) 2.8 (1.2–6.5)
G3 6/41 (15%) 17 (0–47) 80 (0–174) 3.7 (1.3–11.9)
p73-positive
Yes 17/41 (41%) 6 (0–17) 132 (45–219)
No 24/41 (59%) 49 (29–69) 320 4.9 (2.2–10.5)
p53 mutation
Yes 15/41 (37%) 6 (0–18) 120 (66–174)
No 26/41 (63%) 45 (25–65) 260 4.2 (2.0–8.9)
p53 wild-type and
p73-negative 20/41 60 (38–82) >320
p73-positive or
p53 mutation 21/41 5 (0–15) 132 (64–200) 6.2 (2.6–14.5)
aCalculation not possible (insufficient number of patients within the category).Clone DO-7, dilution 1:1000; DakopattsR, Denmark). Two
sections from two different paraffin-embedded tumour tissue
blocks were examined and scored independently by two of us in
the absence of any clinical or pathological information. The posi-
tivity of the markers (ISEL-positive cells and p53-positive tumour
cell nuclei) was assessed by counting an average number of 800
tumour cells, in sections of 200 cells each in four different fields of
every tumour. For p73 evaluation, we scored a tumour as positive
in case of at least 10% positive tumour cell nuclei. Two slides were
counted in every case, leading to a total of 1600 evaluated tumour
cells for each carcinoma. An eyepiece integration grid was used to
ensure that cells were evaluated only once. Stained tumour cells
were considered to be positive, using a light microscope (magni-
fied 400 ´).
The intra-observer error was calculated in a preliminary exami-
nation using the same material; we found that at least 250 tumour
cell nuclei needed to be assessed in order to have the results fall
within the 5% of the estimated real mean with a probability of
95%. To minimize inter-observer error, all counts were performed
separately. In three cases, in which conflicting numbers of positive
cells were evaluated, recounting was performed to obtain a
concordance of opinion.
Statistics
Differences in frequencies between subgroups were analysed
with the Kruskal–Wallis test and the Mann–Whitney U-test for
unpaired samples. Correlation coefficients were calculated
according to Pearson, and c2 statistics were used for contingency
tables. Overall observed survival functions and probabilities were
estimated with the Kaplan–Meier method. The log-rank test was
used to detect differences between survival curves for stratified
variables. Identification of relevant prognostic factors were
performed with univariate Cox regression analyses. The signifi-
cance level was defined as P < 0.05. The median follow-up of our
patients was 210 days (range: 50–1749 days). No patient was lost
during follow-up.
The medical records of all 41 patients were re-examined to
assess the status of disease at the closing date of the study (30
April, 1998). At this time, eight patients were still alive. All the
patients who died during the follow-up period had intrahepatic and
metastatic disease on their last visit to the oncological outpatient
clinic. We concluded that death in these patients was related to
CCC. Median survival was 210 days (95% confidence interval
(CI) 156, 264 days), and the 1-year survival rate was 31% (95%
CI: 17, 45).
RESULTS
Histopathological features
The pathological data are summarized in Table 1.
p73 immunohistochemistry
Out of 41 tumours examined, p73 immunostaining was found in
17/41 cases (32%). Within these tumours, we generally observed a
strong immunoreactivity of the tumour cell nuclei. With few excep-
tions, the cytoplasm was negative (Figure 2). p73 did not stain in all
malignant cells of a tumour. Furthermore, the staining intensity
varied within the tumour, without a predominant localization.
Mitotic, apoptotic or necrotic cells were uniformly negative.
In the case of surrounding, non-neoplastic liver tissue, normal
hepatocytes were occasionally seen to be slightly positive. In
p73 and p53 in cholangiocellular carcinoma 1071
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Figure 1 Western blot (immunoblot) analysis of seven cholangiocellular carcinomas (CC) (Lanes 1–7). Immunoblot analysis of p73- (left) and p53 protein
(right). (A) Detection of p73 and p53 protein in cholangiocellular carcinoma. A total of 50 mg cellular protein in each track was subjected to SDS-PAGE (12%)
and blotted to nitrocellulose. Blots were then incubated with p73 antiserum ([left] and p53-antibody (Clone DO-7; Dakopatts, Denmark) [right] (see also Materials
and Methods). In case 3, 5 and 7 an additional band for p73a was observed, as described by Khaghad et al (1997). (B) Identical gels stained with Coomassie
blue. The reduction of size was due to the gel drying procedure. Histopathological data of the tumours examined: Lane 1: well (G1) differentiated CC, Stage IIIA;
Lane 2: well (G1) differentiated CC, Stage I; Lane 3: moderately (G2) differentiated CC, Stage IIIA; Lane 4: moderately (G2) differentiated CC, Stage IIIA; Lane
5: well (G1) differentiated CC, Stage IIIB; Lane 6: moderately (G2) differentiated CC, Stage IIIA; Lane 7: moderately (G2) differentiated CC, Stage IVAcontrast to the corresponding tumours, however, only very few
nuclei (less than 1%) expressed p73. Bile duct epithelial cells were
uniformly negative, as it was the fibrovascular stroma within the
tumour. We failed to find any correlation of staining to other
histopathological parameters examined. In particular, there were
no relationships between p73 expression and tumour size, cellular
differentiation or tumour stage (Table 2).
p53 mutations
Mutations of the p53 gene were detected in 15/41 cases (36%). Point
mutations of the p53 gene were detected in 14/41 cases; in one case,
a microdeletion was observed. We did not find a mutation in non-
cancerous tissue. In all cases, the p53 gene mutations were clustered
within evolutionary conserved regions, especially in exons 4 and 7.
The most common change was a C®T and G®C transition (Table
3). In two cases, silent mutations were found. There was no signifi-
cant correlation between tumour stage, lymph node metastases,
grade, proliferation and apoptosis and p53 mutation.
Performing immunohistochemistry, positive tumour cell nuclei,
indicating a p53 mutation, were detected in 14/41 cases (34%)
(Figure 3). A difference between mutation status and immuno-
histochemistry was observed in one tumour. In this case, a one
base pair deletion was found in codon 250 of exon 7, whereas p53
immunohistochemistry was negative.
The number of p53-positive tumour cells varied from case to
case, with a considerable intratumourous heterogeneity (Figure 3).
Performing a semiquantitative assessment of p53 immuno-
reactivity (according to Sun et al, 1992; Hui et al, 1997), neither
the staining intensity nor the number of positive cells correlated to
the mutation pattern or to other histopathological parameters
(Table 3). Non-neoplastic liver tissue was always immunohisto-
chemically p53-negative.
Apoptosis
Positive ISEL staining was observed in nuclei and nuclear frag-
ments with the morphological characteristics of apoptosis (Figure
4). There was no preferential localization of apoptotic cells inside
the tumour. In CCC, the apoptotic index (defined as number of
apoptotic cells per 100 tumour cells) ranged between 0.1 and 1.2,
with a mean of 0.56 (± 0.38). We failed to observe a statistical
significant relationship between p53 mutation or p73 expression
and occurrence of apoptotis within a given tumour.
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Table 2 p73 expression according to stage of disease (according to UICC)
and grade (according to WHO)
p73-positive p73-negative
Stage
I 0/41 1/41 (2%)
II 0/41 7/41 (17%)
IIIA 7/41 (17%) 14/41 (34%)
IIIB 3/41 (7%) 0/41
IVA 7/41 (17%) 2/41 (5%)
Grading
G1 3/41 (7%) 11/41 (27%)
G2 11/41 (27%) 10/41 (24%)
G3 3/41 (7%) 3/41 (7%)
Figure 2 p73 immunostaining of cholangiocellular carcinoma of the liver –
brown reaction product within the tumour cell nuclei (DAB used as
chromogen, counterstained with haematoxylin, original magnification: ´ 40)
Figure 4 Apoptotic cells (red reaction product, indicated by arrows,
arrowheads), assessed by ISEL (in-situ end-labelling) technique
(counterstained with haematoxylin, original magnification: ´ 40)
Figure 3 p53 immunostaining of cholangiocellular carcinoma of the liver –
red reaction product within the tumour cell nuclei (Fast red used as
chromogen, counterstained with haematoxylin, original magnification: ´ 20)Survival rate
The survival analysis took into account the following variables:
p73 immunostaining, p53 mutational status, apoptosis, UICC
tumour stage (Sobin and Wittekind, 1997), grading, vascular
invasion, multiplicity, satellites, dysplasia, inflammatory reaction,
necrosis, and patients’ age.
As expected, UICC stage, extent of the primary tumour (pT
category), presence of lymph node metastases (pN category) and
histological grade of tumour differentiation, were significant prog-
nostic parameters. Univariate analysis showed p73 and p53 to be
predictors of survival. There was a significant difference in
survival between patients with tumours showing p73 expression
and those whose tumours did not. The median survival time for
p73-positive tumours was 132 days. In contrast, tumours without
detectable p73 protein had a survival time of 320 days (Figure 5).
Patients with mutations of the p53 gene had a poor prognosis as
well. Tumours lacking p53 mutations, and p73 expression, had a
significantly longer survival time than those with mutations and/or
expression (Table 1).
Multiplicity, satellites, inflammatory infiltrate, dysplasia within
the non-tumourous liver and patients’ age all lacked prognostic
p73 and p53 in cholangiocellular carcinoma 1073
British Journal of Cancer (1999) 80(7), 1069–1074 © 1999 Cancer Research Campaign 
Table 3 p53 mutation, p73 overexpression in cholangiocellular carcinomas
Exon Stage Grade Codon Mutation Amino acid substitution Immunohistochemistry
p53 p73
4 IIIA 1 125 ACG®AAG Thr®Lys ++ +
4 IIIA 2 62 GAA®GAGa Glu®Glu +++ +
4 IIIB 1 54 TTC®TTTa Phe®Phe + –
4 IVA 1 84 GCC®GGC Ala®Gly ++ +
5 IVA 2 175 CGC®CAC Arg®His +++ +
5 IVA 2 178 CAC®AAC His®Asn ++ –
5 IIIA 3 179 CAT®CTT His®Leu ++ +
6 IIIA 2 202 CGT®CCG Arg®Pro +++ +
7 IIIB 3 249 AGG®ACG Arg®Thr + +
7 IIIA 3 226 GGC®GCC Gly®Ala ++ +
7 IIIB 1 245 GGC®AGC Gly®Ser ++ +
7 IIIA 3 250 1 bp del frame shift – +
8 IVA 3 319 AAG®GAG Lys®Glu ++ –
8 IIIA 2 282 CGG®TGG Arg®Trp + –
8 IIIA 2 273 CGT®TGT Arg®Lys +++ +
aSilent mutations, no amino acid substitutions. p53 immunohistochemistry: positivity assessment according to (11, 13): negative (–) < 1% positive nuclei; weakly
positive (+): single positive cells (10–30%); moderately positive (++): numerous positive cells (30–60%); strongly positive (+++): more than 60% positive tumour
cells.
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Figure 5 Survival according to p73 immunostainingsignificance. The odds ratios (OR) for all factors examined are
given in Table 1. Performing multivariate analysis, only pT
category and pN category had an independent prognostic impact.
DISCUSSION
Mutation of the p53 tumour suppressor gene is one of the most
frequent genetic aberrations in human epithelial tumours, almost
half of all primary tumours contain mutant p53 alleles. Recently, a
novel gene with significant sequence homology to the DNA
binding, transactivation and oligomerization domain of p53 was
found (Kaghad et al, 1997). It was shown that p73 could activate
transcription of p53-responsive genes and inhibit cell growth in a
p53-like manner. As with wild-type p53, stable overexpression of
p73 inhibits growth of a neuroblastoma cell line by inducing apop-
tosis (Jost et al, 1997). We therefore examined the relationship
between mutational status of p53 and expression of p73 protein
and the extent of apoptotic cell death in a given tumour. In chol-
angiocellular carcinoma, we found mutations within the p53 gene
in 15/41 cases (37%). The frequency and also the mutation pattern
we found were in concordance with the data from the literature
(Ohashi et al, 1995). Eleven out of 15 tumours with mutations of
p53 also had detectable p73. In contrast, within these 26 tumours
harbouring wild-type p53, p73 positivity occurred in 6/41 cases
only. These findings might suggest that mutation and disruption of
p53 results in an up-regulation of p73.
In hepatocellular carcinomas with detectable mutations of the
p53 gene, the expression of the cell cycle inhibitor p21WAF1/CIP1 was
found to be significantly reduced (Hui et al, 1997). The remark-
able homology between p73 and p53, together with the ability of
p73 to induce the expression of p21WAF1/CIP1 (Clurman et al, 1997;
Jost et al, 1997), might suggest that p73 acts, at least in part, as
a transcription factor. A possible explanation for elevated p73
in cholangiocellular carcinoma, therefore, is that disruption of
normal p53 function results in compensatory or deleterious up-
regulation of p73 expression. Thus, either mutant p53 or reduction
of p21 may trigger an increase of p73 expression. This may
explain why p73 is highly expressed in tumours with p53 mutation
and also why there was no detectable mutation in the p73 gene.
Another possible mechanism may be responsible for the p73
overexpression in cholangiocellular carcinomas: wild-type p53
protein, present in minute concentrations and with a short half-life
in normal tissue, is not detected immunohistochemically (Sun et
al, 1992). In the case of mutated p53, a protein with a longer half-
life is present due to a lower rate of degradation, resulting in accu-
mulation of p53 protein. This mechanism enables the detection of
p53 in immunohistochemistry (Uhlman et al, 1994). For p73, a
similar mechanism may be responsible for its accumulation in a
subset of hepatocellular carcinomas.
However, we and others (Mai et al, 1998; Nomoto et al, 1998;
Takahashi et al, 1998) could not find any specific somatic muta-
tion of p73. These findings strongly suggest that p73 may play an
important role in tumorigenesis through overexpression of wild-
type p73 rather than as a tumour suppressor.
Our results with a median survival time for patients with
cholangiocellular carcinoma are in concordance with the rates
published in the literature (Ohashi et al, 1995). Long-term survival
can only be achieved in case of small tumours, which can be
resected curatively. Therefore, it is urgent to identify factors that
can predict the prognosis of patients after tumour removal more
precisely so that adjuvant therapy can be provided to different
patient groups. Our results with a prognostic influence of p53 and
p73 in univariate survival analysis could favour these two markers
for a better prognostic assessment in an individual patient.
However, we are aware that only a limited number of cases have
been investigated. Therefore, the actual prognostic value of the
two markers needs to be tested and proved in further, multicentric
studies with an adequate number of patients and standardized
treatment procedures (R0 resection), and that are within a speci-
fied stage of disease and were assessed by employing identical
methods.
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